title: ÐÑÐµÐ½ÐºÐ° Ð°ÑÑÐ¾ÑÐ¸Ð°ÑÐ¸Ð¸ Ð°Ð»Ð»ÐµÐ»ÑÐ½Ð¾Ð³Ð¾ Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ° rs823144 Ð¸ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð° RAB29 Ñ Ð±Ð¾Ð»ÐµÐ·Ð½ÑÑ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Evaluation of the association of allelic variant rs823144 and RAB29 gene expression with Parkinsons disease
Creators: name: Ð¢ÐºÐ°ÑÐµÐ½ÐºÐ¾, ÐÑÑÐ¾ÑÐ¸Ð½ÑÑ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2024
Subjects: Ð±Ð¾Ð»ÐµÐ·Ð½Ñ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°
Rab29
Ð°Ð»Ð»ÐµÐ»ÑÐ½ÑÐ¹ Ð²Ð°ÑÐ¸Ð°Ð½Ñ
ÑÐ°ÑÑÐ¾ÑÐ°
ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ñ Ð³ÐµÐ½Ð°
ÑÐ¸ÑÐº ÑÐ°Ð·Ð²Ð¸ÑÐ¸Ñ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ
Parkinsons disease
allelic variant
frequency
gene expression
risk of developing the disease

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¾ÑÐµÐ½ÐºÐµ Ð°ÑÑÐ¾ÑÐ¸Ð°ÑÐ¸Ð¸ Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ° rs823144 Ð³ÐµÐ½Ð° RAB29 Ñ Ð±Ð¾Ð»ÐµÐ·Ð½ÑÑ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð° (ÐÐ) Ð² Ð¡ÐµÐ²ÐµÑÐ¾-ÐÐ°Ð¿Ð°Ð´Ð½Ð¾Ð¼ ÑÐµÐ³Ð¸Ð¾Ð½Ðµ Ð Ð¾ÑÑÐ¸Ð¸. Ð ÑÐ¾Ð´Ðµ ÑÐ°Ð±Ð¾ÑÑ Ð±ÑÐ»Ð° Ð¾ÑÐµÐ½ÐµÐ½Ð° ÑÐ°ÑÑÐ¾ÑÐ° Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ° rs823144 Ð³ÐµÐ½Ð° RAB29 Ð² Ð³ÑÑÐ¿Ð¿Ðµ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ Ð¸ Ð½ÐµÐ²ÑÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸ Ð·Ð´Ð¾ÑÐ¾Ð²ÑÑ Ð¸Ð½Ð´Ð¸Ð²Ð¸Ð´ÑÑÐ¼Ð¾Ð² (ÐºÐ¾Ð½ÑÑÐ¾Ð»Ñ) Ð² Ð¡ÐµÐ²ÐµÑÐ¾-ÐÐ°Ð¿Ð°Ð´Ð½Ð¾Ð¼ ÑÐµÐ³Ð¸Ð¾Ð½Ðµ Ð Ð¾ÑÑÐ¸Ð¸, Ð° ÑÐ°ÐºÐ¶Ðµ Ð¾ÑÐµÐ½ÐµÐ½Ð° Ð°ÑÑÐ¾ÑÐ¸Ð°ÑÐ¸Ñ Ð´Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ° Ð³ÐµÐ½Ð° RAB29 Ñ ÑÑÐ¾Ð²Ð½ÐµÐ¼ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð° RAB29 Ð² Ð¼Ð¾Ð½Ð¾Ð½ÑÐºÐ»ÐµÐ°ÑÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð² Ð³ÑÑÐ¿Ð¿Ðµ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ Ð¸ ÐºÐ¾Ð½ÑÑÐ¾Ð»Ðµ. ÐÐ»Ñ ÑÑÐ¾Ð³Ð¾ Ð² ÑÐ¾Ð´Ðµ Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÑÐºÐ¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ Ð±ÑÐ» ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐ°Ð½ Ð¼ÐµÑÐ¾Ð´ ÑÐºÑÐ¸Ð½Ð¸Ð½Ð³Ð° rs823144 Ð³ÐµÐ½Ð° RAB29 Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ Ð¿Ð¾Ð»Ð¸Ð¼ÐµÑÐ°Ð·Ð½Ð¾Ð¹ ÑÐµÐ¿Ð½Ð¾Ð¹ ÑÐµÐ°ÐºÑÐ¸Ð¸ (ÐÐ¦Ð ) Ð¸ Ð¿Ð¾ÑÐ»ÐµÐ´ÑÑÑÐµÐ³Ð¾ ÑÐµÑÑÑÐ¸ÐºÑÐ¸Ð¾Ð½Ð½Ð¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð°. ÐÐ¾Ð´ÑÐ²ÐµÑÐ¶Ð´ÐµÐ½Ð¸Ðµ ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐ¾Ð² ÑÐºÑÐ¸Ð½Ð¸Ð½Ð³Ð° rs823144 Ð³ÐµÐ½Ð° RAB29 Ð¾ÑÑÑÐµÑÑÐ²Ð»ÑÐ»Ð¾ÑÑ ÑÐµÐºÐ²ÐµÐ½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸ÐµÐ¼ Ð¿Ð¾ Ð¡ÐµÐ½Ð³ÐµÑÑ. Ð£ÑÐ¾Ð²ÐµÐ½Ñ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð° RAB29 Ð¾ÑÐµÐ½Ð¸Ð²Ð°Ð»ÑÑ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ ÐºÐ¾Ð»Ð¸ÑÐµÑÑÐ²ÐµÐ½Ð½Ð¾Ð¹ ÐÐ¦Ð  Ð² ÑÐµÐ¶Ð¸Ð¼Ðµ ÑÐµÐ°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð²ÑÐµÐ¼ÐµÐ½Ð¸. ÐÑÐ°Ð¹Ð¼ÐµÑÑ Ð±ÑÐ»Ð¸ Ð¿Ð¾Ð´Ð¾Ð±ÑÐ°Ð½Ñ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¿ÑÐ¾Ð³ÑÐ°Ð¼Ð¼Ñ Primer3. Ð­Ð½Ð´Ð¾Ð½ÑÐºÐ»ÐµÐ°Ð·Ñ Ð±ÑÐ»Ð¸ Ð¿Ð¾Ð´Ð¾Ð±ÑÐ°Ð½Ñ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ NEBcutter. Ð¡ÑÐ°ÑÐ¸ÑÑÐ¸ÑÐµÑÐºÐ°Ñ Ð¾Ð±ÑÐ°Ð±Ð¾ÑÐºÐ° Ð´Ð°Ð½Ð½ÑÑ Ð¿ÑÐ¾Ð²Ð¾Ð´Ð¸Ð»Ð°ÑÑ Ð² ÑÑÐ°ÑÐ¸ÑÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÑÑÐµÐ´Ðµ R. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð±ÑÐ»Ð° Ð¾ÑÐµÐ½ÐµÐ½Ð° ÑÐ°ÑÑÐ¾ÑÐ° Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ° rs823144 Ð³ÐµÐ½Ð° RAB29 Ð² Ð³ÑÑÐ¿Ð¿Ðµ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ Ð² Ð¡ÐµÐ²ÐµÑÐ¾-ÐÐ°Ð¿Ð°Ð´Ð½Ð¾Ð¼ ÑÐµÐ³Ð¸Ð¾Ð½Ðµ Ð Ð¾ÑÑÐ¸Ð¸, ÐºÐ¾ÑÐ¾ÑÐ°Ñ ÑÐ¾ÑÑÐ°Ð²Ð¸Ð»Ð° 38% Ð² Ð³ÑÑÐ¿Ð¿Ðµ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ Ð¸ 43% Ð² ÐºÐ¾Ð½ÑÑÐ¾Ð»ÑÐ½Ð¾Ð¹ Ð³ÑÑÐ¿Ð¿Ðµ, Ð²Ð°ÑÐ¸Ð°Ð½Ñ rs823144 Ð³ÐµÐ½Ð° RAB29 Ð½Ðµ Ð°ÑÑÐ¾ÑÐ¸Ð¸ÑÐ¾Ð²Ð°Ð½ Ñ ÑÐ¸ÑÐºÐ¾Ð¼ ÑÐ°Ð·Ð²Ð¸ÑÐ¸Ñ ÐÐ Ð² Ð¡ÐµÐ²ÐµÑÐ¾-ÐÐ°Ð¿Ð°Ð´Ð½Ð¾Ð¼ ÑÐµÐ³Ð¸Ð¾Ð½Ðµ Ð Ð¾ÑÑÐ¸Ð¸. Ð£ÑÐ¾Ð²ÐµÐ½Ñ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð° RAB29 Ð½Ðµ ÑÐ°Ð·Ð»Ð¸ÑÐ°Ð»ÑÑ Ð¼ÐµÐ¶Ð´Ñ ÐÐ Ð¸ ÐºÐ¾Ð½ÑÑÐ¾Ð»ÐµÐ¼ Ð¸ Ð½Ðµ Ð·Ð°Ð²Ð¸ÑÐµÐ» Ð¾Ñ Ð²Ð°ÑÐ¸Ð°Ð½ÑÐ° rs823144 Ð³ÐµÐ½Ð° RAB29 (p&gt;0,05).
description: This work is devoted to the evaluation of the association of the rs823144 variant of the RAB29 gene with Parkinsons disease (PD) in the North-West region of Russia. In the course of this work we evaluated the frequency of the rs823144 variant of the RAB29 gene in a group of PD patients and neurologically healthy individuals (control) in the North-West region of Russia, as well as evaluated the association of this RAB29 gene variant with the level of RAB29 gene expression in peripheral blood mononuclear cells in a group of PD patients and controls. For this purpose, a method for screening rs823144 of the RAB29 gene based on polymerase chain reaction (PCR) and subsequent restriction analysis was developed during undergraduate work. Confirmation of the screening results of rs823144 of the RAB29 gene was performed by Sanger sequencing. The expression level of the RAB29 gene was assessed by quantitative real-time PCR. Primers were selected using Primer3 software. Endonuclease were selected using NEBcutter. Statistical processing of data was performed in R environment. As a result, the frequency of the rs823144 variant of the RAB29 gene in the group of patients with PD in the North-West region of Russia was estimated, which was 38% in the group of patients with PD and 43% in the control group; the rs823144 variant of the RAB29 gene is not associated with the risk of PD development in the North-West region of Russia. The level of RAB29 gene expression did not differ between PD and controls and did not depend on the rs823144 variant of the RAB29 gene (p&gt;0.05).